Sergio Caravita1, Andrea Faini2, Carolina Lombardi2, Mariaconsuelo Valentini2, Francesca Gregorini2, Jessica Rossi2, Paolo Meriggi3, Marco Di Rienzo3, Grzegorz Bilo2, Piergiuseppe Agostoni4, Gianfranco Parati5. 1. Istituto Auxologico Italiano (Drs Caravita, Faini, Lombardi, Valentini, Rossi, Bilo, and Parati and Ms Gregorini); Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Department of Cardiovascular, Neural and Metabolic Sciences, S. Luca Hospital; the Department of Health Sciences (Drs Caravita and Parati). 2. Istituto Auxologico Italiano (Drs Caravita, Faini, Lombardi, Valentini, Rossi, Bilo, and Parati and Ms Gregorini). 3. University of Milano-Bicocca; Polo Tecnologico (Dr Meriggi and Mr Di Rienzo). 4. Biomedical Technology Department, Fondazione Don Carlo Gnocchi Onlus; Centro Cardiologico Monzino (Dr Agostoni)IRCCS; and the Department of Clinical Sciences and Community Health University of Milan, Milan, Italy. 5. Istituto Auxologico Italiano (Drs Caravita, Faini, Lombardi, Valentini, Rossi, Bilo, and Parati and Ms Gregorini); Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Department of Cardiovascular, Neural and Metabolic Sciences, S. Luca Hospital; the Department of Health Sciences (Drs Caravita and Parati). Electronic address: gianfranco.parati@unimib.it.
Abstract
OBJECTIVE:Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sex-related difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. METHODS:Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level off treatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. RESULTS: Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. CONCLUSIONS: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. TRIAL REGISTRY: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu.
RCT Entities:
OBJECTIVE: Nocturnal periodic breathing occurs more frequently in men than in women with various clinical and pathophysiologic conditions. The mechanisms accounting for this sex-related difference are not completely understood. Acetazolamide effectively counteracts nocturnal periodic breathing, but it has been investigated almost exclusively in men. Our aim was to explore possible determinants of nocturnal periodic breathing in a high-altitude setting both in men and in women. We hypothesized that increased hypoxic chemosensitivity in men could be associated with the development of nocturnal periodic breathing at altitude more frequently than in women, and that acetazolamide, by leftward shifting the CO2 ventilatory response, could improve nocturnal periodic breathing at altitude in a sex-independent manner. METHODS: Forty-four healthy lowlanders (21 women), randomized to acetazolamide or placebo, underwent cardiorespiratory sleep studies at sea level off treatment and under treatment on the first night after arrival at a 4,559-m altitude. Hypoxic and hypercapnic chemosensitivities were assessed at sea level. RESULTS:Men, more frequently than women, exhibited increased hypoxic chemosensitivity and displayed nocturnal periodic breathing at altitude. Acetazolamide leftward shifted the CO2 set point and, at altitude, improved oxygenation and reduced periodic breathing in both sexes, but to a larger extent in men. Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. CONCLUSIONS: The greater severity of periodic breathing during sleep displayed by men at altitude could be attributed to their increased hypoxic chemosensitivity. Acetazolamide counteracted the occurrence of periodic breathing at altitude in both sexes, modifying the apneic threshold and improving oxygenation. TRIAL REGISTRY: EU Clinical Trials Register, EudraCT; No.: 2010-019986-27; URL: https://www.clinicaltrialsregister.eu.
Authors: Víctor H Nieto Estrada; Daniel Molano Franco; Roger David Medina; Alejandro G Gonzalez Garay; Arturo J Martí-Carvajal; Ingrid Arevalo-Rodriguez Journal: Cochrane Database Syst Rev Date: 2017-06-27
Authors: Alain Riveros-Rivera; Thomas Penzel; Hanns-Christian Gunga; Oliver Opatz; Friedemann Paul; Lars Klug; Michael Boschmann; Anja Mähler Journal: Front Physiol Date: 2022-05-24 Impact factor: 4.755
Authors: Stephan Pramsohler; Robert Schilz; Andreas Patzak; Linda Rausch; Nikolaus C Netzer Journal: Sleep Breath Date: 2019-04-10 Impact factor: 2.816
Authors: Christopher N Schmickl; Shane A Landry; Jeremy E Orr; Kazuo Chin; Kimihiko Murase; Johan Verbraecken; Shahrokh Javaheri; Bradley A Edwards; Robert L Owens; Atul Malhotra Journal: Chest Date: 2020-08-05 Impact factor: 9.410
Authors: Gianfranco Parati; Piergiuseppe Agostoni; Buddha Basnyat; Grzegorz Bilo; Hermann Brugger; Antonio Coca; Luigi Festi; Guido Giardini; Alessandra Lironcurti; Andrew M Luks; Marco Maggiorini; Pietro A Modesti; Erik R Swenson; Bryan Williams; Peter Bärtsch; Camilla Torlasco Journal: Eur Heart J Date: 2018-05-01 Impact factor: 29.983
Authors: Jennifer Petkovic; Janet Jull; Manosila Yoganathan; Omar Dewidar; Sarah Baird; Jeremy M Grimshaw; Kjell Arne Johansson; Elizabeth Kristjansson; Jessie McGowan; David Moher; Mark Petticrew; Bjarne Robberstad; Beverley Shea; Peter Tugwell; Jimmy Volmink; George A Wells; Margaret Whitehead; Luis Gabriel Cuervo; Howard White; Monica Taljaard; Vivian Welch Journal: Trials Date: 2020-04-03 Impact factor: 2.279